{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:15:28Z","timestamp":1780409728483,"version":"3.54.1"},"reference-count":162,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Therapeutic cancer vaccines are a promising immunotherapy approach in genitourinary (GU) cancers, designed to stimulate antitumor immune responses through antigen-specific T-cell activation. Although agents such as bacillus Calmette\u2013Gu\u00e9rin in bladder cancer and sipuleucel-T in prostate cancer have shown success, vaccine monotherapy has generally produced limited clinical benefit due to tumor heterogeneity, poor immune infiltration, and immunosuppressive tumor microenvironments. Multiple vaccine platforms have demonstrated safety and immunogenicity in prostate, renal cell, and urothelial cancers, but efficacy remains modest. Current strategies focus on multi-antigen targeting, improved antigen presentation, and combination therapies with immune checkpoint inhibitors, radiotherapy, and targeted agents to enhance antitumor activity. Advances in personalized vaccine design and delivery systems are driving progress, though challenges such as manufacturing complexity, cost, and biomarker development remain. Ongoing translational and clinical research will be critical to improving the effectiveness of vaccine-based immunotherapy in GU malignancies.<\/jats:p>","DOI":"10.3390\/vaccines14060497","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:45:08Z","timestamp":1780404308000},"page":"497","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions"],"prefix":"10.3390","volume":"14","author":[{"given":"Haider","family":"Altay","sequence":"first","affiliation":[{"name":"Hematology and Medical Oncology, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Al-Hashimi","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Matthews","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"DeAlessandro","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1363-8738","authenticated-orcid":false,"given":"Ghanshyam H.","family":"Ghelani","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.hoc.2018.12.001","article-title":"Cancer Vaccines","volume":"33","author":"DeMaria","year":"2019","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-017-0457-4","article-title":"Immunotherapy in genitourinary malignancies","volume":"10","author":"Mehta","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri2817","article-title":"Prostate cancer as a model for tumour immunotherapy","volume":"10","author":"Drake","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e70020","DOI":"10.1002\/ctm2.70020","article-title":"NY-ESO-1 antigen: A promising frontier in cancer immunotherapy","volume":"14","author":"Alsalloum","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41698-025-01016-2","article-title":"Mucin-1: A promising pan-cancer therapeutic target","volume":"9","author":"Grewal","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s11658-024-00654-x","article-title":"Research progress of MUC1 in genitourinary cancers","volume":"29","author":"Mao","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Baldin, A.V., Isayev, O., Werner, J., Zamyatnin, A.A., and Bazhin, A.V. (2021). Cancer Vaccines: Antigen Selection Strategy. Vaccines, 9.","DOI":"10.3390\/vaccines9020085"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhu, S., Chen, J., and Zeng, H. (2023). Our Current Understanding of the Heterogeneity in Prostate Cancer and Renal Cell Carcinoma. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041526"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/0008-5472.CAN-23-2042","article-title":"Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines","volume":"84","author":"Pounraj","year":"2024","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1003190","DOI":"10.37349\/ei.2025.1003190","article-title":"Neoantigen vaccines: Advancing personalized cancer immunotherapy","volume":"5","author":"Aljabali","year":"2025","journal-title":"Explor. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-016-1801-1","article-title":"Lessons learned from cancer vaccine trials and target antigen choice","volume":"65","author":"Butterfield","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bahmad, H.F., Jalloul, M., Azar, J., Moubarak, M.M., Samad, T.A., Mukherji, D., Al-Sayegh, M., and Abou-Kheir, W. (2021). Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.652747"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1007\/s13346-021-01036-y","article-title":"Overcoming physical stromal barriers to cancer immunotherapy","volume":"11","author":"Chung","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"63138","DOI":"10.18632\/oncotarget.11257","article-title":"Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension","volume":"7","author":"Peixoto","year":"2016","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Smith, V., Lee, D., Reardon, M., Shabbir, R., Sahoo, S., Hoskin, P., Choudhury, A., Illidge, T., and West, C.M.L. (2023). Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108956"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nm.2172","article-title":"Lipid accumulation and dendritic cell dysfunction in cancer","volume":"16","author":"Herber","year":"2010","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Huang, J., Ojo, A., Tsao, S., Horowitz, A., Kyprianou, N., and Tsao, C.-K. (2025). Overcoming Immune Evasion in the Prostate Tumor Microenvironment: Novel Targeted Strategies to Improve Treatment Outcomes. Cancers, 17.","DOI":"10.3390\/cancers17213441"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2018.03.025","article-title":"Dysfunction of antigen processing and presentation by dendritic cells in cancer","volume":"113","author":"Roche","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0167-5699(95)80033-6","article-title":"Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance","volume":"16","author":"Ferrone","year":"1995","journal-title":"Immunol. Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e012217","DOI":"10.1136\/jitc-2025-012217","article-title":"Shared epitopes create safety and efficacy concerns in several cancer vaccines","volume":"13","author":"Kellermann","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(19970201)30:2<73::AID-PROS1>3.0.CO;2-L","article-title":"Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen","volume":"30","author":"Xue","year":"1997","journal-title":"Prostate"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/CJI.0b013e3181a80e0d","article-title":"Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: A phase 2 study in patients with recurrent prostate cancer","volume":"32","author":"Kouiavskaia","year":"2009","journal-title":"J. Immunother."},{"key":"ref_31","first-page":"19","article-title":"Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer","volume":"3","author":"Sharma","year":"2003","journal-title":"Cancer Immun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/pros.20025","article-title":"NY-ESO-1 protein expression and humoral immune responses in prostate cancer","volume":"59","author":"Fossa","year":"2004","journal-title":"Prostate"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1158\/1078-0432.CCR-10-1811","article-title":"Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients","volume":"17","author":"Karbach","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10637-013-9960-9","article-title":"HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer","volume":"32","author":"Sonpavde","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/CJI.0b013e3181891574","article-title":"Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF","volume":"31","author":"Sharma","year":"2008","journal-title":"J. Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1169353","DOI":"10.1080\/2162402X.2016.1169353","article-title":"SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade","volume":"5","author":"Xue","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1084\/jem.184.2.465","article-title":"Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo","volume":"184","author":"Boczkowski","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2796.2003.01140.x","article-title":"DNA vaccines: A review","volume":"253","author":"Liu","year":"2003","journal-title":"J. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/sj.bjc.6602019","article-title":"A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer","volume":"91","author":"Pavlenko","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00262-006-0241-8","article-title":"Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells","volume":"56","author":"Johnson","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.19.01701","article-title":"Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer","volume":"37","author":"McNeel","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2395680","DOI":"10.1080\/21645515.2024.2395680","article-title":"Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer","volume":"20","author":"Tonelli","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e008067","DOI":"10.1136\/jitc-2023-008067","article-title":"Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer","volume":"11","author":"McNeel","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00262-012-1317-2","article-title":"Sipuleucel-T immune parameters correlate with survival: An analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer","volume":"62","author":"Sheikh","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1158\/1078-0432.CCR-14-2334","article-title":"Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome","volume":"21","author":"GuhaThakurta","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"dju268","DOI":"10.1093\/jnci\/dju268","article-title":"Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer","volume":"106","author":"Fong","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial","volume":"81","author":"Schellhammer","year":"2013","journal-title":"Urology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/2326-6066.CIR-23-0652","article-title":"High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance","volume":"12","author":"Saeed","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1002\/cncr.32445","article-title":"Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer","volume":"125","author":"Higano","year":"2019","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2006.03.061","article-title":"Therapeutic dendritic cell vaccination of patients with renal cell carcinoma","volume":"50","author":"Berntsen","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/CJI.0b013e3181833818","article-title":"Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: A clinical phase 1\/2 trial","volume":"31","author":"Berntsen","year":"2008","journal-title":"J. Immunother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40425-014-0030-4","article-title":"A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma","volume":"2","author":"Matsushita","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wang, D., Zhang, B., Gao, H., Ding, G., Wu, Q., Zhang, J., Liao, L., and Chen, H. (2014). Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-251"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Ellinger, J., Ritter, M., and Schmidt-Wolf, I.G.H. (2020). Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12092471"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-11-2442","article-title":"Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma","volume":"18","author":"Liu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/PPO.0b013e3182325e63","article-title":"Viral vector-based therapeutic cancer vaccines","volume":"17","author":"Larocca","year":"2011","journal-title":"Cancer J."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Secl\u00ec, L., Leoni, G., Ruzza, V., Siani, L., Cotugno, G., Scarselli, E., and D\u2019alise, A.M. (2023). Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316591"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2217\/fon.15.120","article-title":"Development of PROSTVAC immunotherapy in prostate cancer","volume":"11","author":"Singh","year":"2015","journal-title":"Future Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e000655","DOI":"10.1136\/jitc-2020-000655","article-title":"Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer","volume":"8","author":"Sater","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/13543780902997928","article-title":"Prostvac-VF: A vector-based vaccine targeting PSA in prostate cancer","volume":"18","author":"Madan","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/oncolo\/oyad058","article-title":"Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer","volume":"28","author":"Madan","year":"2023","journal-title":"Oncologist"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e000217","DOI":"10.1136\/jitc-2019-000217","article-title":"Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: Case report","volume":"8","author":"Zeng","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Peshin, S., Dharia, A., Moka, N., and Skelton, W.P.t. (2025). A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions. Cancers, 17.","DOI":"10.20944\/preprints202507.2249.v1"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cell.2020.09.053","article-title":"Can Personalized Neoantigens Raise the T Cell Bar?","volume":"183","author":"Zaidi","year":"2020","journal-title":"Cell"},{"key":"ref_70","first-page":"76","article-title":"Challenges in Manipulating Immune System to Treat Prostate Cancer","volume":"58","author":"Samija","year":"2019","journal-title":"Acta Clin. Croat."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11912-021-01084-0","article-title":"Prostate Cancer Immunotherapy-Finally in From the Cold?","volume":"23","author":"Runcie","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ucl.2020.07.008","article-title":"Immunotherapy for Localized Prostate Cancer: The Next Frontier?","volume":"47","author":"Patel","year":"2020","journal-title":"Urol. Clin. N. Am."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Xu, P., Wasielewski, L.J., Yang, J.C., Cai, D., Evans, C.P., Murphy, W.J., and Liu, C. (2022). The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081778"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Burotto, M., Singh, N., Heery, C.R., Gulley, J.L., and Madan, R.A. (2014). Exploiting synergy: Immune-based combinations in the treatment of prostate cancer. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00351"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kalina, J.L., Neilson, D.S., Comber, A.P., Rauw, J.M., Alexander, A.S., Vergidis, J., and Lum, J.J. (2017). Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers, 9.","DOI":"10.3390\/cancers9020013"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Meng, L., Collier, K.A., Wang, P., Li, Z., Monk, P., Mortazavi, A., Hu, Z., Spakowicz, D., Zheng, L., and Yang, Y. (2023). Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells, 13.","DOI":"10.3390\/cells13010034"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00262-010-0935-9","article-title":"A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: Clinical and immunological findings","volume":"60","author":"Oudard","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1479-5876-9-178","article-title":"Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: Results from a phase I\/II trial","volume":"9","author":"Baek","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9994","DOI":"10.1038\/s41598-023-37234-6","article-title":"An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model","volume":"13","author":"Ueki","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1074\/jbc.M809456200","article-title":"Comparing Pooled Peptides with Intact Protein for Accessing Cross-presentation Pathways for Protective CD8+ and CD4+ T Cells","volume":"284","author":"Zhang","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"CT270","DOI":"10.1158\/1538-7445.AM2023-CT270","article-title":"Abstract CT270: Immunogenicity of PGV_001 neoantigen vaccine in a Phase-I clinical trial, across various types of cancers in adjuvant setting","volume":"83","author":"Saxena","year":"2023","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s43018-025-00966-7","article-title":"Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: A phase 1 trial","volume":"6","author":"Saxena","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: Platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7150\/jca.20059","article-title":"Cancer vaccine: Learning lessons from immune checkpoint inhibitors","volume":"9","author":"Ye","year":"2018","journal-title":"J. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.4161\/21645515.2014.973317","article-title":"Antigen-specific vaccines for cancer treatment","volume":"10","author":"Tagliamonte","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3145742","DOI":"10.1155\/2017\/3145742","article-title":"Manipulation of Innate and Adaptive Immunity through Cancer Vaccines","volume":"2017","author":"Sayour","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/emboj.2012.333","article-title":"The cancer antigenome","volume":"32","author":"Heemskerk","year":"2013","journal-title":"EMBO J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-13-1334","article-title":"Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors","volume":"20","author":"Wu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1002\/cncr.32361","article-title":"Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma","volume":"125","author":"Mantia","year":"2019","journal-title":"Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Dianat-Moghadam, H., Nedaeinia, R., Keshavarz, M., Azizi, M., Kazemi, M., and Salehi, R. (2023). Immunotherapies targeting tumor vasculature: Challenges and opportunities. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1226360"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"101199","DOI":"10.1016\/j.xcrm.2023.101199","article-title":"Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach","volume":"4","author":"Sridaran","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nm.3915","article-title":"Toward understanding and exploiting tumor heterogeneity","volume":"21","author":"Alizadeh","year":"2015","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14760584.2018.1506332","article-title":"Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy","volume":"17","author":"Collins","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.semradonc.2014.07.002","article-title":"Combination regimens of radiation therapy and therapeutic cancer vaccines: Mechanisms and opportunities","volume":"25","author":"Hodge","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"403","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: Promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Vohra, J., Barbosa, G.R., and Reis, L.O. (2025). mRNA and DNA-Based Vaccines in Genitourinary Cancers: A New Frontier in Personalized Immunotherapy. Vaccines, 13.","DOI":"10.3390\/vaccines13090899"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3389\/fimmu.2019.01392","article-title":"Determinants for Neoantigen Identification","volume":"10","author":"Fajardo","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PAP.0000000000000383","article-title":"Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors","volume":"30","author":"Bahlinger","year":"2023","journal-title":"Adv. Anat. Pathol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"109542","DOI":"10.1016\/j.biopha.2019.109542","article-title":"Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy","volume":"120","author":"Zhang","year":"2019","journal-title":"BioMed. Pharmacother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"eadv6445","DOI":"10.1126\/sciadv.adv6445","article-title":"Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy","volume":"11","author":"Cai","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13073-020-00731-8","article-title":"Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy","volume":"12","author":"Reustle","year":"2020","journal-title":"Genome Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13059-025-03763-8","article-title":"MHCquant2 refines immunopeptidomics tumor antigen discovery","volume":"26","author":"Scheid","year":"2025","journal-title":"Genome Biol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Wu, A.C., Nakamura, Y., and Kiyotani, K. (2025). Advances in Neoantigen-Based Cancer Vaccines. Cancers, 18.","DOI":"10.3390\/cancers18010144"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Flores-Islas, A.K., Rico-Fuentes, C., Sierra-D\u00edaz, E., Garc\u00eda-Chagoll\u00e1n, M., Pereira-Su\u00e1rez, A.L., Zepeda-Nu\u00f1o, J.S., Moreno-Ortiz, J.M., and Ram\u00edrez-De-Arellano, A. (2026). Immunotherapeutic Strategies for Prostate Cancer: A Comprehensive Review. Cancers, 18.","DOI":"10.3390\/cancers18020255"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Bou-Dargham, M.J., Sha, L., Sang, Q.A., and Zhang, J. (2020). Immune landscape of human prostate cancer: Immune evasion mechanisms and biomarkers for personalized immunotherapy. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07058-y"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-025-00877-w","article-title":"Alternative splicing: From tumorigenesis to neoantigen-mediated cancer immunotherapy","volume":"14","author":"Lv","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","volume":"22","author":"Peng","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1021\/acsnano.3c04471","article-title":"A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists","volume":"18","author":"Baljon","year":"2024","journal-title":"ACS Nano"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/vaccines3030662","article-title":"Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy","volume":"3","author":"Fan","year":"2015","journal-title":"Vaccines"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"17699","DOI":"10.1039\/D4NR01780C","article-title":"Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy","volume":"16","author":"Wells","year":"2024","journal-title":"Nanoscale"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e202318515","DOI":"10.1002\/anie.202318515","article-title":"Development of Mannosylated Lipid Nanoparticles for mRNA Cancer Vaccine with High Antigen Presentation Efficiency and Immunomodulatory Capability","volume":"63","author":"Lei","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12951-024-02812-x","article-title":"Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA","volume":"22","author":"Kong","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1039\/D5BM00839E","article-title":"Influence of structural modifications in synthetic vectors of lipid adjuvants on mRNA vaccine delivery","volume":"13","author":"Chilumula","year":"2025","journal-title":"Biomater. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12951-025-03800-5","article-title":"mRNA vaccines: Immunogenicity and quality characteristics","volume":"24","author":"Quan","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1039\/D4PM00309H","article-title":"The rise of mRNA therapeutic vaccines","volume":"2","author":"Du","year":"2025","journal-title":"RSC Pharm."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Wang, J., Ding, Y., Chong, K., Cui, M., Cao, Z., Tang, C., Tian, Z., Hu, Y., Zhao, Y., and Jiang, S. (2024). Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines, 12.","DOI":"10.3390\/vaccines12101148"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2014From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.imbio.2017.06.002","article-title":"Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines","volume":"222","author":"Rueda","year":"2017","journal-title":"Immunobiology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1039\/C9NR08958F","article-title":"Nanoparticle formulated vaccines: Opportunities and challenges","volume":"12","author":"Lung","year":"2020","journal-title":"Nanoscale"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12935-021-01972-2","article-title":"Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"200333","DOI":"10.1016\/j.tvr.2025.200333","article-title":"Oncolytic virus and immunogenic cell death in cancer therapy","volume":"20","author":"Cao","year":"2025","journal-title":"Tumour Virus Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","article-title":"Oncolytic virotherapy and tumor microenvironment modulation","volume":"25","author":"Bautista","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"ltaf033","DOI":"10.1093\/immadv\/ltaf033","article-title":"Turning the tide: Harnessing vaccines and viruses to fight cancer","volume":"5","author":"Blee","year":"2025","journal-title":"Immunother. Adv."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nri3254","article-title":"Cross-presentation by dendritic cells","volume":"12","author":"Joffre","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"E856","DOI":"10.1152\/ajpendo.00484.2005","article-title":"Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: A physiological role for testosterone and\/or its metabolites","volume":"290","author":"Page","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ccr.2005.01.027","article-title":"Androgen ablation mitigates tolerance to a prostate\/prostate cancer-restricted antigen","volume":"7","author":"Drake","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"Formenti","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Alard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","article-title":"Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1186\/s12967-025-06867-8","article-title":"Reversing the \u201ccold\u201d tumor microenvironment: The role of neoantigen vaccines in prostate cancer","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: An overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.urolonc.2015.02.007","article-title":"Biomarkers for immunotherapy in genitourinary malignancies","volume":"34","author":"Slovin","year":"2016","journal-title":"Urol. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Klar","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat. Med."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Lu, L., Lu, X., and Luo, W. (2025). Personalized Cancer Vaccines: Current Advances and Emerging Horizons. Vaccines, 13.","DOI":"10.3390\/vaccines13121231"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Ho, S.-Y., Chang, C.-M., Liao, H.-N., Chou, W.-H., Guo, C.-L., Yen, Y., Nakamura, Y., and Chang, W.-C. (2023). Current Trends in Neoantigen-Based Cancer Vaccines. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030392"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","article-title":"Preclinical and clinical development of neoantigen vaccines","volume":"28","author":"Li","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_158","first-page":"274","article-title":"Neoantigen cancer vaccines: A new star on the horizon","volume":"21","author":"Li","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Hao, Q., Long, Y., Yang, Y., Deng, Y., Ding, Z., Yang, L., Shu, Y., and Xu, H. (2024). Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens. Vaccines, 12.","DOI":"10.3390\/vaccines12070717"},{"key":"ref_160","first-page":"199","article-title":"Personalized Vaccines: Unlocking the Next Era of Medical Innovation in Cancer Immunotherapy","volume":"4","author":"Murphy","year":"2025","journal-title":"Cancer Screen. Prev."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/erv.11.188","article-title":"Technologies for enhanced efficacy of DNA vaccines","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Maiorano, B.A., Schinzari, G., Ciardiello, D., Rodriquenz, M.G., Cisternino, A., Tortora, G., and Maiello, E. (2021). Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. Vaccines, 9.","DOI":"10.20944\/preprints202105.0205.v1"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/497\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:23:53Z","timestamp":1780406633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":162,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["vaccines14060497"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14060497","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}